March 2021 - Page 2 of 3 - PsychedelicNewsWire (PNW)

FridayMar 19, 2021 1:00 pm

European Firms May Dominate Psychedelics Market in Foreseeable Future

Most pioneering research on the potential of psychedelics to treat various mental health conditions has originated from the United States. In the 1950s, Humphry Osmond, a psychiatrist from California, started experimenting with LSD, a psychedelic drug that he administered to patients. MAPS, a leading not-for-profit organization that conducts research on psychedelics, was established in the late 1980s in the United States. However, with regard to commercializing psychedelics to help treat various disorders such as addiction and depression, it is not American but European companies that are at the forefront. The last year can attest to this. Last year, a biotech…

ThursdayMar 18, 2021 2:00 pm

Former Australian Defense Chief Advocates for Psychedelic Drugs to Be Rescheduled

Advocates calling for psychedelic-assisted therapy had in 2020 applied to reschedule psychedelic drugs under controlled drugs from prohibited substances. The drugs include oxycodone, methadone and morphine. Last month, the Therapeutic Goods Administration issued an interim decision to not revise the Poisons Standard, which would have allowed mental health professionals access to the drugs. Retired Admiral Christopher Barrie, who was the Defense Forces Chief from 1998–2002, stated that psychedelic drugs such as MDMA and psilocybin should be reclassified so that they could be used to treat mental health conditions such as PTSD and depression. Barrie is the director of Mind Medicine…

WednesdayMar 17, 2021 3:10 pm

Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) Takes Milestone Step Toward Offering Product Across Canada

PULL subsidiary has submitted application to Health Canada to amend license to permit sales of product The submission follows recent announcement that Pure Extracts inked distribution agreement with an important Canadian Licensed Producer (“LP”) PULL plans on distributing exclusive vape, edible products to retail buyers across Canada As a result of the its recently inked distribution agreement with an important Canadian LP, Pure Extracts Technologies (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) through its wholly owned subsidiary, Pure Extracts Manufacturing Corp., will be selling its exclusive, high-quality cannabis extract products to provincially authorized distributors and retailers throughout Canada by the end of April.…

WednesdayMar 17, 2021 2:15 pm

Veterans’ Groups Demand Access to Psychedelics, Marijuana Through VA

Leaders of various military veterans’ organizations have issued a message to congressional legislators stating that federal psychedelics and cannabis laws were out of date and needed to be reformed. This, they said, would provide service members with alternative treatment options for conditions such as PTSD. Additionally, three veterans service organizations presented written testimonies during the House and Senate Veterans Affairs Committees hearings recently. The testimonies supported a change in policy that would allow more research to be conducted on medical marijuana and broaden access to medical marijuana, with another arguing that loosening restrictions would allow veterans to use psychedelics as…

MondayMar 15, 2021 2:45 pm

Global Survey Discovers Many People Are Self-Medicating with Psychedelics

A survey conducted recently that includes 110,000 individuals who answered various questions that focused on their use of drugs, found that roughly 6% of them used psychedelics to deal with their mental health issues and emotional issues. The survey found that the drugs most commonly used by the percentage which represented about 6,500 individuals, were ketamine, psilocybin, MDMA and LSD. The Global Drug Survey 2020 included examples of people microdosing on psilocybin mushrooms or LSD on their own, as well as instances where psychedelics were consumed in a way that was unregulated but under the keen eye of another individual.…

FridayMar 12, 2021 3:00 pm

Activists in Spokane, Washington, Call for Decriminalization of Psilocybin

Local activists from Decriminalize Spokane recently filed an initiative that, if approved, may make Spokane the latest city to decriminalize hallucinogenic mushrooms in the United States. The measure would prohibit officials from using the city’s resources or funds to enforce laws that impose criminal penalties for the distribution, growing, transportation, possession or use of psilocybin mushrooms. This is in addition to making the distribution, growing and personal possession of psilocybin for individuals aged 21 and over among the lowest enforcement priorities of law enforcement. Decriminalize Spokane plans to qualify the measure for the city’s ballot. The initiative includes terms forbidding…

WednesdayMar 10, 2021 2:00 pm

UC San Diego Researchers to Test Psychedelics Potential in Treating Amputees

The Steven & Alexandra Cohen Foundation recently gave a $1.3 million grant to UC San Diego’s Psychedelics and Health Research Initiative. The grant will be used to finance a clinical trial evaluating the therapeutic potential of psilocybin in managing phantom limb pain. Psilocybin is the active psychedelic compound found in many fungus species, including magic mushrooms. On the other hand, phantom limb pain refers to painful sensations that originate from the part of an individual’s limb that is no longer present, such as an amputated leg. This grant will finance the first placebo-controlled randomized human clinical trial, which will be…

TuesdayMar 09, 2021 3:09 pm

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) Upsizes Its Bought Deal Offering Due to Surge in Demand

Cybin's latest offering generated exceptional demand; announces upsize of "bought deal" offering Burgeoning psychedelic sector attracts investors’ attention as compound may prove effective in mental health treatments. Cybin appears set for rapid growth as research accelerates, public acceptance grows. Cybin (NEO: CYBN) (OTCQB: CLXPF), a biotech company focused on psychedelic therapeutics for various psychiatric and neurological conditions, has announced that it has upsized the terms of its "bought deal" offering due to strong demand. The deal size, previously announced at CDN$20,025,000, has increased to aggregate gross proceeds of CDN$30,015,000 as the underwriters have agreed to purchase 13,340,000 units of the…

TuesdayMar 09, 2021 11:00 am

New Partnership Formed to Create Microneedle Patch to Deliver Psychedelic Medicines

Researchers from Terasaki Institute for Biomedical Innovation (“TIBI”) have designed a microneedle patch that will be used to deliver drugs and is currently being modified for use in micro-dosing psychedelic substances. These compounds include psilocybin mushrooms, LSD and MDMA, all of which have the potential to treat severe pain as well as mental health conditions such as depression and anxiety. The microneedle patch, GeIMA, has been developed using a gelatinous substance, and its surface is made up of tiny microneedles that would contain the drug or drugs to be administered to an individual. When the patch is applied to the…

MondayMar 08, 2021 11:20 am

USF, Partners Obtain DEA Authorization to Study Psychedelics for CNS Disorders

In partnership with the University of South Florida (“USF”) and its chemical screening and purification facility, Psilera Bioscience has acquired approval from the DEA to study psilocin, which is an active psychedelic component found in psilocybin mushrooms and ayahuasca tea, psilocybin and DMT (N,N-dimethyltryptamine). USF and Psilera join other universities across the United States that are also conducting psychedelic research on various psychedelic compounds. Psilera’s objective is to be the pioneer psychedelics company to develop patient-friendly and noninvasive DMT delivery methods. The company’s CSO and co-founder, Dr. Jackie on Salm, explained that the company was focused on developing new delivery…

News and publishing service for psychedelic related companies

Contact us: 415.949.5050

Month: March 2021